Royan Institute is a renowned center committed to multidisciplinary, campus-wide, integration and collaboration of academic and medical personnel for understanding male/ female infertility, embryo development, stem cell biology, and biotechnology. Royan Institute provides comprehensive services for the infertility treatment, regenerative medicine/cell therapy, production of recombinant proteins and development of biological products.
The preliminary findings of a Phase I clinical trial involving researchers from Royan Institute have been published, evaluating the safety and tolerability of three intrathecal administrations of allogeneic mesenchymal stromal cells (MSCs) derived from umbilical cord Wharton’s jelly in children with autism spectrum disorder (ASD).
MedPath, an international platform specializing in medical information, clinical trials, and health technologies, has published a report highlighting the development and approval of WhartoCell, a cell therapy product developed by Royan Institute.
